Rimei Nishimura
Overview
Explore the profile of Rimei Nishimura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
1471
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suganuma Y, Ishiguro M, Ohno T, Nishimura R
Diabetol Int
. 2024 Oct;
15(4):806-813.
PMID: 39469555
Aims: We aimed to investigate potential predictors of effectiveness of SGLT2 inhibitors (SGLT2i) in individuals with type 1 diabetes (T1D) on sensor-augmented pump (SAP) therapy. Methods: We included individuals with...
2.
Sekiguchi K, Matoba K, Nagai Y, Nagao S, Ohashi S, Mitsuyoshi E, et al.
Biochem Biophys Res Commun
. 2024 Oct;
736:150874.
PMID: 39467357
The mineralocorticoid receptor (MR) is a member of the nuclear receptor family that was initially identified to regulate blood pressure through its ability to modulate kidney sodium handling in response...
3.
Horikawa C, Takahara M, Katakami N, Takeda Y, Takeuchi M, Fujihara K, et al.
Diabetes Obes Metab
. 2024 Oct;
27(1):394-406.
PMID: 39466701
Aims: Many guidelines recommend increases in potassium intake. However, the relationship of dietary potassium intake with incident cardiovascular disease (CVD) has not been examined in those with type 2 diabetes...
4.
Watada H, Asbjornsdottir B, Nishida T, Nishimura R, Yamamoto Y, Yamauchi T, et al.
Diabetes Obes Metab
. 2024 Sep;
26(12):5882-5895.
PMID: 39344833
Aim: To explore the efficacy and safety of once-weekly insulin icodec (icodec) in Japanese adults (≥20 years old) with type 2 diabetes from the global ONWARDS 1, 2 and 4...
5.
Ohno T, Tsujino D, Nishimura R
Expert Rev Endocrinol Metab
. 2024 Sep;
19(6):507-512.
PMID: 39235079
Objective: Time in Tight Range (TITR), defined as the percentage of time within the glucose range of 70 to 140 mg/dL, is anticipated to be challenging to maintain without causing...
6.
Yabe D, Hamamoto Y, Kawanami D, Nishimura R, Terauchi Y, Amadid H, et al.
J Diabetes Investig
. 2024 Aug;
15(11):1566-1577.
PMID: 39172634
Aims/introduction: PIONEER REAL Japan was a non-interventional prospective study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice. Materials And Methods: Adults naïve to injectable glucose-lowering...
7.
Miwa T, Yoshida S, Nakajima A, Koto R, Nishimura R
Diabetol Int
. 2024 Aug;
15(3):483-494.
PMID: 39101196
Aims: Assess medication persistence and adherence for dipeptidyl peptidase-4 inhibitors (DPP-4i) administered once weekly (QW), once daily (QD), and twice daily (BID) among patients with type 2 diabetes (T2D), and...
8.
Koto R, Yoshida S, Nakajima A, Miwa T, Nishimura R
Diabetol Int
. 2024 Aug;
15(3):632-637.
PMID: 39101189
Aims: To assess the glycemic control of once-weekly (QW) and other administration frequencies for dipeptidyl peptidase-4 inhibitors (DPP-4i) in patients with type 2 diabetes in a real-world setting. Methods: A...
9.
Bouchi R, Kondo T, Ohta Y, Goto A, Tanaka D, Satoh H, et al.
Diabetol Int
. 2024 Aug;
15(3):327-345.
PMID: 39101173
The Japan Diabetes Society (JDS) adopted a sweeping decision to release consensus statements on relevant issues in diabetes management that require updating from time to time and launched a "JDS...
10.
Yamashiro K, Takahashi H, Hayashino Y, Origasa H, Izumi K, Tajima N, et al.
Diabetol Int
. 2024 Aug;
15(3):315-326.
PMID: 39101169
In the large-scale, prospective, observational JDCP study, a total of 5944 people with type 2 diabetes (mean age at baseline, 61.4 years old; women, 39.9%; and duration of diabetes, 10.8 ...